PELICAN: A quality of life instrument for childhood asthma

Study Protocol of two Randomized Controlled Trials in Primary and Specialized Care in the Netherlands

Stephanie van Bragt1*, Lisette van den Bemt1, Bart Thoonen1, Chris van Weel1, Peter Merkus2 and Tjard Schermer1

Abstract

Background: Asthma is one of the major chronic health problems in children in the Netherlands. The Pelican is a paediatric asthma-related quality of life instrument for children with asthma from 6–11 years old, which is suitable for clinical practice in primary and specialized care. Based on this instrument, we developed a self-management treatment to improve asthma-related quality of life. The Pelican intervention will be investigated in different health care settings. Results of intervention studies are often extrapolated to other health care settings than originally investigated. Because of differences in organization, disease severity, patient characteristics and care provision between health care settings, extrapolating research results could lead to unnecessary health costs without the desired health care achievements. Therefore, interventions have to be investigated in different health care settings when possible. This study is an example of an intervention study in different health care settings. In this article, we will present the study protocol of the Pelican study in primary and specialized care.

Method/design: This study consists of two randomized controlled trials to assess the effectiveness of the Pelican intervention in primary and specialized care. The trial in primary care is a multilevel design with 170 children with asthma in 16 general practices. All children in one general practices are allocated to the same treatment group. The trial in specialized care is a multicentre trial with 100 children with asthma. Children in one outpatient clinic are randomly allocated to the intervention or usual care group. In both trials, children will visit the care provider four times during a follow-up of nine months. This study is registered and ethically approved.

Discussion: This article describes the study protocol of the Pelican study in different health care settings. If the Pelican intervention proves to be effective and efficient, implementation in primary and specialized care for paediatric asthma in the Netherlands will be recommended.

Trial registration: This study is registered by clinicaltrial.gov (NCT01109745)

Keywords: Asthma, Quality of life, Children, Primary care, Specialized care, Self-management, Randomized controlled trial (RCT)

© 2012 van Bragt et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Asthma [1] is the most common chronic disease in childhood in the Netherlands. Its prevalence ranges from 3% in children aged 5–9 years to 3.7% in children aged 10–14 years [2,3]. Although the prevalence is leveling off [4], asthma remains a significant burden for the child, family and the society at large [5]. In the Netherlands, children with intermittent and mild asthma are usually treated by a family physician, while patients with more severe or uncontrolled asthma are treated by specialized paediatric care [6]. This implies that children with asthma treated in primary and specialized care may differ in features like disease severity and complexity, level of symptom control, functional status and co-morbidity [7]. Recent reports point to substantial room for improvement in the management of childhood asthma [8-11]. Poor adherence to therapy and inadequately treatment are two important reasons why asthma is uncontrolled [9]. Poor adherence has been associated with discrepancies between the perceived relevance of treatment goals between patients and their healthcare providers. Usual care for children with asthma focuses on reducing morbidity and mortality by maintaining optimal asthma control, while asthmatic children want to live a normal life with as few limitations from their asthma as possible [12]. Taking the child’s perception into account in the management of its asthma could result in achieving treatment goals of patients and providers and contribute to patient centered care. However, recent studies pointed out that input of children and their parents into asthma management is only taken into account by health care providers during a minority (6 to 10%) of medical visits [13].

One of the important treatment outcomes showing a patient’s perspective is health related quality of life (HRQL). HRQL is a complex of all aspects of an individual’s subjective experience that relate to health, disease, disability and impairment, which is usually measured in physical, emotional, cognitive and social dimensions [14-17]. A HRQL questionnaire adds significant information about the functional impairments of a patient to clinical and physiological characteristics. Previous studies have shown that the most important HRQL components for children are consequences of asthma on peer relationships, dependence on medication, shortness of breath, cough, limitations in activities and limitations due to tobacco smoke exposure [18,19].

We have previously developed a child friendly web based tool to assess asthma-related quality of life in paediatric asthma patients, using the so-called ‘Pelican instrument’. In this paper, we describe the rationale for, and the designs of two randomized controlled trials (RCTs) that are based on the implementation of the Pelican instrument. In these trials the effectiveness of its implementation will be evaluated in both primary and specialized care setting in the Netherlands. Both trials are optimally adjusted in methodological design to meet the needs of the concerned care setting. Because of the known differences in healthcare organization and patient characteristics, it is important to establish possible effects of the treatment in both healthcare settings separately. In the past, results from specialized care studies have often been extrapolated into primary care, and vice versa [20,21]. Knowing that several important differences exist between these care setting, it is likely that this might lead to ineffective, unnecessary or expensive health care without the desired health achievements. Therefore, it is crucial to evaluate such interventions in primary as well as in specialized care.

Hypothesis

The primary hypothesis of the Pelican study is that a self management treatment based on HRQL information (Pelican instrument) is able to improve HRQL on the PAQLQ-S (> 0.5 points) in children with asthma from 6–11 years old in primary and specialized care with a proportional difference in favour of intervention relative to usual care of 25% of children. Furthermore, it is also hypothesized that the instrument could improve asthma control and satisfaction with care of parents.

Research questions

The primary research question

- Is the Pelican intervention in primary and specialized health care effective in improving HRQL of children with asthma?

The secondary research questions

- Is the Pelican intervention in primary and specialized health care effective in improving HRQL of the parents of children with asthma?
- Is the Pelican intervention in primary and specialized health care effective in improving asthma control of children with asthma?
- Does the Pelican intervention improve patient-doctor relationship and satisfaction with delivered care in primary and specialized health care?
- Is the Pelican instrument able to detect and improve psychosocial problems?
- Is the Pelican intervention user friendly in regular medical care and cost-effective in a primary and specialized care setting?

Methods/design

Study design

This study consists of two RCTs: one in primary care and one in specialized care. Because the study design,
sample size calculation and treatment allocation differ between the trials, these aspects are described separately. All other aspects apply to both trials.

170 participants in primary care will be recruited from 16 general practices in the Netherlands. The primary care study is a multicentre parallel group study with a hierarchical or nested design. This means that all participating patients within a general practices will be allocated to the same treatment group (usual care or intervention group). During visits the usual care group receives care of the GP according NHG (Dutch GP Association) guidelines [22]. Besides usual care, the intervention group will receive recommendations based on the Pelican outcome by a practice nurse as well.

The most optimal study design for intervention studies is a multilevel design to avoid contamination between usual care and the intervention, which is applied in the primary care trial. There are, however, not enough outpatient clinics in the Netherlands to be able to use a multilevel design in specialized care. This means that specialized nurses provide care for both patients of the intervention and those of the usual care group. 100 participants in specialized care will be recruited in 5 outpatient clinics in the Netherlands. The usual care group receives care according to NVK (Dutch Association of paediatric) guidelines of paediatric asthma in the Netherlands of a care provider (e.g. paediatrician or nurse) [23]. The intervention group receives an intervention with the Pelican outcome by an asthma nurse complementary to usual care.

**Sample size calculation**

A multilevel power calculation was performed for the trial in primary care based on the percentage of children with an improvement of 0.5 points on the PAQLQ instrument score (Δ0.5 is the minimum clinically important difference (MCID) for the PAQLQ) [14,24]. We consider a proportional difference in favour of intervention relative to usual care of 25% of children with a MCID to be clinically relevant. Based on the assumptions ICC = 0.04, α = 0.05, 1-β = 0.80, 20% of usual care group with a 0.5 points increase in PAQLQ score, and dropout rate of 15%, a total of 170 children with asthma needs to be included from 16 GPs.

A power calculation was performed for the trial in specialized care based on the percentage of children with an improvement of 0.5 points on the PAQLQ instrument score. We consider a proportional difference in favour of intervention relative to usual care of 25% of children with a MCID to be clinically relevant. Based on the assumptions α = 0.05, 1-β = 0.80, 10% of usual care group with a 0.5 points increase in PAQLQ score, and dropout rate = 15%, a total of 100 children with asthma needs to be included.

**Selection phase**

In both trials children aged 6 to 12 years with asthma diagnosed by a physician will be recruited. Moreover, children must have used their asthma medication (i.e., bronchodilators and/or inhaled corticosteroids) for at least six weeks during the previous year to confirm ‘active asthma’. Exclusion criteria for these studies are: 1) a comorbide condition that significantly influences the HRQL, 2) not being able to attend a regular school class and 3) insufficient skill of Dutch language.

Parents of children are informed about the study by verbal explanation and an information brochure. For children, age-adjusted study information is provided on the website of the study. Written informed consent of both official caregivers will be obtained to ensure voluntary and anonymous participation. In accordance with the guidelines on scientific research with underage individuals, children may be withdrawn from the study at any time if they object [25].

**Randomisation: treatment allocation**

Enrolment of participants will be performed by the general practices or outpatient clinics. Participants can be allocated to the usual care or intervention group. In both trials, the minimisation technique will be used to allocate participants to treatment. Minimisation is an advanced randomisation technique as described by Pocock [26,27]. The balance between both groups will be kept with consideration of prognostic factors (categorical variables) as described below with a computer program called Minim.

In the primary care trial general practices will be allocated balanced on the following prognostic factors: 1) number of potential participants for study within GP (<18 or ≥18 patients with the diagnosis asthma between 6–11 years old) and 2) usual asthma care (absence of structured asthma care, structured asthma care for adults or structured asthma care for children).

In the specialized care trial the minimisation technique will be used to force treatment allocation of individual participants with consideration of the prognostic factors age (6–8 years old and 9–11 years old) and level of asthma control (ACQ score <1 and ACQ score ≥1).

**Pelican instrument**

The paediatric Electronic quality of Life Instrument for Asthmatic children in the Netherlands or Pelican is a web-based asthma-related quality of life questionnaire that is presented as a web-based computer game. It is effortless to complete, easy to understand (questions are read aloud) and full of attractive sounds and pictures. While playing the game, the child answers questions about his or her experience of asthma. Item selection for the Pelican was based on children’s personal perspectives that were obtained using focus groups [18]. Items are
concrete aspects of day-to-day life with asthma what
makes them an easy starting point for treatment and are
scored in burden experience on a 5-point Likert scale
ranging from ‘no burden at all’ (0 points) to ‘very high bur-
den’ (5 points). Scores are visually supported by emoticons.
Besides overall quality of life, the instrument has the ability
to priorities issues of asthma bothering the patient most.

**Intervention**
The intervention is a self-management treatment based
on the patient’s reply to the Pelican questionnaire. Treat-
ment is provided by a specialized nurse with the object-
ive to improve the patient’s asthma-related quality of
life. The nurse is trained during a 2-hour meeting in this
intervention with theoretic background, video instruc-
tions and role playing exercises. Supplementary to the
training, a minimum of five evaluation moments are
included during the trial.

The child fills out the Pelican before the scheduled visit
and the outcome is forwarded to the nurse. The interven-
tion is based on the theory of behaviour change and
shared decision making [28]. The health care provider
supports the parent and child to explore their needs and
treatment goals (according SMART principles [29]) and
think about solutions for disease related problems and
challenges. Together, the parent, child and nurse work
on a treatment plan to improve disease management
resulting in better disease outcomes. The treatment plan
is a mutual agreement that is specific, acceptable and
realistic. During the next visit, the nurse will evaluate the
effectiveness of the treatment plan: why was it successful
or unsuccessful to achieve treatment goals. If not success-
ful, the care provider will explore the causes (lack of
knowledge/skills, motivational, practical or social barriers)
and evaluate whether they can be resolved.

**Study parameters**
The primary outcome of the study is HRQL as measured
with the PAQLQ-S (standardised activities). The Dutch
version of the PAQLQ was validated in children ≥ 6 years
and has psychometric properties similar to those reported
for the original PAQLQ [30]. Also the HRQL of the main
caregiver is assessed with the PACQLQ (paediatric asthma
caregiver quality of life questionnaire) [31].

Secondary outcomes are asthma control, psychosocial
problems and satisfaction with care. Asthma control is
measured by questionnaires such as the Asthma Control
Questionnaire (ACQ) [32], the Childhood Asthma Control
Test (C-ACT) [33] and the Asthma Therapy Assessment
Questionnaire (ATAQ) [34]. Psychometric properties of all
asthma control instruments were found to be good
[32,33,35]. Lung function with reversibility (pre- en post-
FVC, pre- and post- FEV1) and Fraction of exhaled NO¹
(FeNO) will be assessed according international guidelines
[36,37]. Psychosocial problems will be measured with the
Dutch version of Strengths and Difficulties Questionnaire
(SDQ) that shows good psychometric properties [24]. An
adapted version of the Patient-Doctor relationship Ques-
tionnaire (PDRQ-9) will be used to measure parent’s satis-
faction with provided care to their child by a care provider
and other patient-doctor relationship aspects [34].

**Data collection**
In the recruitment phase, the parents receive a question-
naire on family characteristics (e.g., socio-economic sta-
tus, family history of respiratory diseases, composition of
family, smoking habits), child asthmatic symptoms,
medication use, attitude towards asthma [35]. All partici-
pants visit the general practices or outpatient clinic four
times during a follow-up period of 9 months. The par-
ents as well as the children fill out a questionnaire at the
start and end of the study to measure HRQL, asthma
control, psychosocial problems and satisfaction with
care. During the first visit, lung function will be mea-
sured of subjects in the primary care trial. In specialized
care, both lung function and fraction exhaled NO will be
measured during the first and last visit. Next, the parents
fill out monthly calendars on asthma control, symptoms
and medication use of their child. Finally, health care
providers, parents and children will be inquired about
the satisfaction and user friendliness of implementation
of the Pelican using structured questionnaires. Since the
Pelican study is a complex intervention, data will be col-
lected for process evaluation.

**Data analysis**
The primary analysis is an intention-to-treat analysis,
however both explanatory and intention-to-treat analy-
ses will be performed. The effect of the Pelican in pri-
mary care will be analysed using multi-level analyses
techniques. The effect of the Pelican in specialized care
will be assessed using multivariate regression models. A
correction for baseline value of the outcome of interest
(e.g., HRQL, asthma control) will be added to the model.

**Process evaluation and cost-effectiveness analysis**
The implementation of the Pelican in health care is a
complex intervention [38]. A detailed process evaluation
is crucial to evaluate what the active ingredients are and
how they are exerting their effect. Potential barriers and
facilitators of implementation are screened in every
phase of the study, starting at the completion of the Peli-
can instrument by the child at home, the use of the Peli-
can instrument during the medical visit by the health
care professional and finally the influence on asthma
specific HRQL [39].

A cost-effectiveness analysis (CEA) from a societal per-
spective will be performed and reported according to
national and international guidelines [40,41]. The costs included will be program costs, direct medical costs and indirect costs measured in their natural units and transformed to costs using real prices and standard reimbursement of expense tariffs. An effect is defined as a relevant change in HRQL (i.e., ΔPAQLQ ≥ 0.5 point) in the denominator and the total of all relevant costs in the nominator.

Ethics
Ethical approval is obtained from the Medical Ethics Committee of the Arnhem-Nijmegen region in the Netherlands. The study protocol is extensively studied by: The Dutch Asthma Foundation, NutsOhra and Radboud University Nijmegen Medical Centre (RUNMC). This trial is registered by clinicaltrial.gov (NCT01109745).

Discussion
Patient-centred care, especially in chronic diseases, has a growing need to implement information on health-related quality of life (HRQL) next to clinical and physiological measures. Although several quality of life instruments for paediatric asthma patients already exist, the Pelican instrument distinguishes itself because of its applicability in regular medical care. In this article, we presented the methodological design of the Pelican study. Our primary research question is whether the use of the Pelican will improve the asthma-related quality of life in children with asthma from 6–11 years old. The secondary research questions are whether the use of the Pelican intervention will improve asthma control, satisfaction with care and HRQL of the parent. Furthermore, it will be evaluated whether the Pelican is able to detect and reduce psychosocial problems. The study consists of two RCTs with a follow-up of nine months performed in primary and specialized care. Although the study design, sample size and treatment allocation of participants differ between both trials, the research questions and data collection will be identical. The trial in primary care will be a multilevel design, while participants within outpatient clinics of specialized care will be randomly allocated to the usual care and intervention group. The Pelican study has a couple of strong characteristics. In this study, we choose to add another HRQL instrument to the data collection besides the Pelican instrument as an independent HRQL measurement to answer our primary research question. Another strong characteristic of this study is that the intervention will be investigated in both principal health care settings for childhood asthma, doing justice to the differences that exist in organisation and patient characteristic between primary and specialized care. For example, paediatric asthma patients in primary care show lower disease severity compared to patients in specialized care [7]. This could imply different levels in room for improvement in HRQL and thus could lead to different effect results. Performing two trials which are methodologically optimised to the health care setting leads to better validity and reliable results of treatment effect and cost-effectiveness analyses. Furthermore, a detailed process evaluation will be done to map barriers and facilitators of the treatment.

However, some drawbacks must be mentioned. It is impossible to perform a double-blind RCT because patients will be aware of the treatment group allocation. In addition, being a subject in an intervention study will cause the Hawthorne effect, easily leading to a favourable response [42–44]. A specific limitation of the primary care trial is the frequency of medical visits. To keep up scientific comparability between the two trials and actively work on a treatment plan with the patient, the frequency of four medical visits during a period of nine months was set. This frequency of medical visits is usual in specialized care but doubled the frequency of visits in primary care compared to the recommendations in national guidelines. Usual care in the primary care study is, therefore, best described as ‘enhanced usual care’ [45]. Increasing contact time between child and care provider may give more favourable results. This effect is expected to be equal in both study arms in the primary care trial. Ideally, a usual care group without any protocol enhancements would have been added to the RCTs. Furthermore, we choose to let the Pelican intervention be performed by a practice nurse. Nurses play an increasing important role in health care for chronic patients, such as diabetes and COPD patients. Involvement of paediatric nurses is already part of usual care in most paediatric outpatient clinics while paediatric asthma management in primary care is usually provided by family physicians without involvement of nurses. A recent study of Kuehle et al. (2011) suggested that the level of asthma control in children managed by an asthma nurse is not inferior to traditional management by primary or specialized care physicians [46]. Our choice of practice nurse involvement was made with the eye on expected future changes in paediatric asthma care in family practices.

A limitation in the specialized care trial is the risk on contamination bias. The specialized nurses in outpatient clinics provide care for patients of the intervention and usual care group. Although nurses were instructed not to use intervention techniques in the usual care group, contamination bias is unavoidable. The trained nurse in outpatient clinics might unintentionally apply training aspects (such as shared decision-making) during treatment of patients in the usual care group and may potentially minimize the difference in outcomes between the two treatment groups.

In conclusion, the aim of this study is to assess the effectiveness of the Pelican in primary and specialized care through a self-management treatment with the aim of improving asthma-related quality of life in children with
asthma from 6–11 years old. If the Pelican proves to be effective and efficient, implementation of this instrument in usual care for paediatric asthma will be recommended. Although the implementation of the Pelican intervention will be evaluated in two almost equal RCTs, it was necessary to adjust the design of both trials to fit the concerning settings. Although, different study design characteristics lead to less comparability between the two trials, the unique feature of this project is that we do not need to extrapolate study outcomes to another care settings based on numerous assumptions, as the intervention is evaluated simultaneously in both major care settings.

Abbreviations
ACQ: Asthma control questionnaire; ATAQ: Asthma therapy assessment questionnaire; ACT: Asthma control test; C-ACD: Childhood asthma control test; FeNO: Fraction exhaled nitric oxide; FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; GP: Family physician/practice; HRQL: Health related quality of life; PACQLO: Paediatric asthma caregiver quality of life questionnaire; PAQ-LQ: Paediatric asthma quality of life questionnaire; Pelican: Paediatric electronic quality of life instrument for childhood asthma instrument in the Netherlands; PDRQ-9: Patient doctor relationship questionnaire; SDQ: Strengths and difficulties questionnaire; UMC: University medical centre.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SvB, LvdB and TS have developed the protocol. LvdB, TS and BT applied for funding. SvB drafted the manuscript with critical input from all authors. All authors read and approved the final manuscript.

Acknowledgements
This trial is funded by grants of the Dutch Asthma Foundation (NAF 3.4.07.043), fonds NutsOhra (0802-74), Nijmegen Centre for Evidence Based Practice (NCEBP) and Radboud University Nijmegen Medical Centre.

Author details
1Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, The Netherlands. 2Department of Paediatric Pulmonology, Radboud University Nijmegen Medical Centre, The Netherlands.

Received: 25 June 2012 Accepted: 15 August 2012 Published: 30 August 2012

References
1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 2004, 59:469–478.
2. Wilga AH, Beckers MC. Complaints and illnesses in children in the Netherlands. Ned Tijdschr Geneeskd 2011, 155:A3464.
3. Cijfers astma (prevalentie, incidentie en sterfte) uit de VTv. 2010. http://www.nationaalkompass.nl/gezondheid-en-delekte/ziekten-en-aandoeningen/ademhalingszwerken/astma/cijfers-astma-prevalentie-incidentie-en-sterfte-uit-de-vtv-2010/.
4. Anandan C, Numutav U, van Schayck OC, Sheikh A: Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010, 65:152–167.
5. O'Connell EJ: The burden of atopy and asthma in children. Allergy 2004, 59:Suppl 78:7–11.
6. Linden M, Gothe H, Ornkel J: Pathways to care and psychological problems of general practice patients in a "gate keeper" and an "open access" health care system: a comparison of Germany and the Netherlands. Soc Psychiatry Psychiatr Epidemiol 2003, 38:650–657.
7. Kuete MC, Vaessen-Verbene AA, Bindels PJ, van Aalderen WM: Children with asthma on inhaled corticosteroids managed in general practice or by hospital paediatricians: is there a difference? Prim Care Respir J 2010, 19:62–67.
8. Schmier JK, Manjunath R, Halpert MT, Jones ML, Thompson K, Diette GB: The impact of inadequately controlled asthma in urban children on quality of life and productivity. Ann Allergy Asthma Immunol 2007, 98:245–251.
9. Kuehni CE FL: Age-related differences in perceived asthma control in childhood: guidelines and reality. Eur Respir J 2002, 20:880–889.
10. Holgate ST, Price D, Valovirta E: Asthma out of control? A structured review of recent patient surveys. BMC Pulm Med 2006, 6(1):52.
11. van Dellen QM, Sterons K, Bindels PJ, Ory FG, Bruil J; van Aalderen WM: Predictors of asthma control in children from different ethnic origins living in Amsterdam. Respir Med 2007, 101:779–785.
12. Guyatt GH, Juniper EF, Griffith LE, Feeny DH, Ferrie PJ: Children and adult perceptions of childhood asthma. Pediatrics 1997, 99:165–168.
13. Sleath BL, Carpenter DM, Sayner R, Ayala GK, Williams D, Davis S, Tudor G, Roberts K: Child and caregiver involvement and shared decision-making during asthma pediatric visits. J Asthma 2011, 48:1022–1031.
14. WHO: The World Health Organisation. Constitution of the World Health Organisation. Geneva: WHO; 1947.
15. Bullinger M: Quality of life: definition, conceptualization and implications - a methodologist’s view. Theoretical Surgery 1991, 61:143–149.
16. Stewart AL, Ware JE Jr, Brook RH: Advances in the measurement of functional status: construction of aggregate indexes. Med Care 1981, 19:473–488.
17. Carr AJ, Gibson B, Robinson PG: Measuring quality of life: Is quality of life determined by expectations or experience? BMJ 2001, 322:1240–1243.
18. van den Bermt L, Kooijman S, Linssen V, Lucassen P, Muris J, Slabbers G, Schermer T: How does asthma influence the daily life of children? Results of focus group interviews. Health Qual Life Outcomes 2010, 8:5.
19. Gallery PMR, Verdyn C, Couriel J: Qualitative study of young peoples and parents beliefs about childhood asthma. Br J Gen Pract 2003, 53:185–190.
20. Raine R, Haines A, Sensky T, Hutchings A, Larkin K, Black N: Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care? BMJ 2002, 325:1082.
21. Holgate ST: The importance of primary care research in the management of respiratory disease. Prim Care Respir J 2012, 21:1–3.
22. Richtlijnen beeld Astma bij Kinderen (M24). http://nhgartsennet.nl/kenniscentrum/k_richtlijnen/k_rhstandaarden/Samenvattingekaartje-NHGStandaard_M24_svkh.htm.
23. Sectie Kinderlongziekten NVvK: Samenvatting van de derde richtlijnen van de Sectie Kinderlongziekten van de NVK. Amsterdam Zuidoost: Hilversum: IJmuidens Londenbaan Graftmedia; 2008.
24. Muris P, Meesters C, van den Berg F: The strengths and difficulties questionnaire (SDQ)–further evidence for its reliability and validity in a community sample of dutch children and Adolescents. Eur Child Adolesc Psychiatry 2003, 12:1–8.
25. Gedragscode bij verzet van minderjarigen die deelnemen aan medisch-wetenschappelijk onderzoek. http://www.ccmo-online.nl/main.asp?pid=21.
26. Freedman LS, White SJ: On the use of Pocock and Simon’s method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1975, 31:691–694.
27. Birkett NJ: Adaptive allocation in randomized controlled trials. Control Clin Trials 1985, 6:146–155.
28. Bandura A: Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977, 84:191–215.
29. Aertschot DV: Praktijkboek voor organisatieontwikkeling van de politie wetenschappelijk onderzoek. Amsterdam Zuidoost: Hilversum: IJmuidens Londenbaan Graftmedia; 2008.
30. Raat H, Bueving HJ, de Jongste JC, Grol MH, Juniper EF, van der Wouden JC: The impact of inadequately controlled asthma in urban children with asthma. Qual Life Res 2005, 14:265–272.
31. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M: Measuring quality of life in the parents of children with asthma. Qual Life Res 1996, 5:27–34.
32. Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR: Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999, 14:902–907.
33. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, Rosenzweig JC, Manjunath R: Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007, 119:817–825.

34. Vollmer WM, Markson LE, O'Connor E, Frazier EA, Berger M, Buist AS: Association of asthma control with health care utilization: a prospective evaluation. Am J Respir Crit Care Med 2002, 165:195–199.

35. Skinner E, Dette G, Gatt-Bergstrom P, Nguyen T, Clark R, Markson L, et al: The Asthma Therapy Assessment Questionnaire (ATAQ) for children and adolescents. Dis Manag 2004, 7:305–313.

36. ATS/ERS: ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005, 171:912–930.

37. Miller M, Hankinson J, Brusasco V, Burgos F, Cassaburi R, Coates A, et al: Standardisation of spirometry. Eur Respir J 2005, 26:319–338.

38. Craig P, Deppie P, Macintyre S, Michie S, Nazareth I, Petticrew M: Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008, 337:a1655.

39. Grol R, Gromishaw J: From best evidence to best practice: effective implementation of change in patients’ care. Lancet 2003, 362:1225–1230.

40. Gold M, Siegel J, Russell L, Weinstein M: Cost-effectiveness in health and medicine. First edth edition. New York: Oxford University Press; 1996.

41. Koopmanschap M, Rutten F: Berekening van kosten van zorg. Vaak onderschat in economische evaluatiestudies. Tijdschr Soc Gezondheidsz 1998, 76:83–88.

42. Roethlisberger F, Dickson W: Management and the worker. MA: Cambridge; 1939.

43. Braunholtz DA, Edwards SJ, Lilford RJ: Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol 2001, 54:217–224.

44. McCannery R, Warnier J, Liffie S, van Haselen R, Griffin M, Fisher P: The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol 2007, 7:30.

45. Freedland KE, Mohr DC, Davidson KW, Schwartz JE: Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med 2011, 73:323–335.

46. Kuethe M, Vaessen-Verberne A, Mulder P, Bindels P, van Alderen W: Paediatric asthma outpatient care by asthma nurse, paediatrician or general practitioner: randomised controlled trial with two-year follow-up. Prim Care Respir J 2011, 20:84–91.